First Quarter 2021
Report Ÿ
Zealand Pharma
12 May 2021
Forward looking statement
This presentation contains "forward-looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products.
The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward- looking statements to be incorrect, and which include, but are not limited to, the occurrence of adverse safety events; risks of unexpected costs or delays; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; product liability claims; and the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations and financial condition.
If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement.
All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the date of this release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
1Q 2021 presentation 12 May 2021 | 2 |
With the Zegalogue approval we have taken another important step in pursuing our ambition as a fully integrated biotech
5x25
Have 5 commercialized products by 2025
Optimize commercial operations
DKK thousand | ||||||||||
Fully operational US | 2,000,000 | |||||||||
infrastructure | 1,500,000 | |||||||||
High prescriber coverage | ||||||||||
1,000,000 | ||||||||||
Established relationships | ||||||||||
500,000 | ||||||||||
with KOLs and HCPs | ||||||||||
0 | ||||||||||
2017 | 2018 | 2019 | 2020 | Q1 2021 | ||||||
Cash & cash equivalents | Restricted cash | Securities | ||||||||
1Q 2021 presentation 12 May 2021 | 3 |
Four strategic objectives to ensure a successful launch of ZEGALOGUE
Presence
Precision
Establish a clear and distinct product positioning with HCPs, patients, and caregivers
Focused execution during the "back to school" season prioritizing high-value customer segments
Access
Support
Establish favorable market access early among top National and Regional Payers, PBMs, and health systems
Address patient and caregiver access and education needs through a "fit for purpose" patient support capability
1Q 2021 presentation 12 May 2021 | 4 |
ZEGALOGUE will launch at the right time in a growing market that is driven by innovation
Launch timed to capture
'Back to school' seasonality
+60% Rx Volume Lift
TRx Volume
Weekly Glucagon Market
Jun Jul Aug Sep Oct
Source: Symphony Health TRx Quantity
Rescue market growing with | Innovation driven market with | |||
new entrants | new entrants capturing share | |||
TRx Units Dispensed (M) | ||||
1.2 | ||||
+10% | ||||
+6% | ||||
0.9 | ~300m | |||
USD | 63% | |||
78% | ||||
0.6 | 100% | |||
1.0
0.90.9
0.3
37% | |||||||||
22% | |||||||||
0.0 | 2019 | 2020 | 2018 | 2019 | 2020 | ||||
2018 | |||||||||
Legacy products | New Entrants | ||||||||
1Q 2021 presentation 12 May 2021 | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Zealand Pharma A/S published this content on 12 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 May 2021 16:47:03 UTC.